Journal article
Treatable Trait Guided Asthma Management: A Feasibility Study
- Abstract:
- Background and Objectives: Treatable trait‐based personalised medicine improves outcomes in severe asthma clinics. We assessed the feasibility of a randomised controlled trial (RCT) of protocolised treatable trait‐guided asthma management in patients not under a severe asthma clinic. Methods: Ten week single‐group cohort study. Participants had a doctor's diagnosis of asthma, Asthma Control Questionnaire‐5 (ACQ‐5) score > 1, and ≥ 1 exacerbation in the last year. Intervention: biomarker‐guided asthma medication according to a protocolised algorithm, targeting traits of type‐2 inflammation and airflow obstruction. Feasibility outcomes: recruitment rates, acceptability of intervention, willingness to enrol in an RCT, need for ‘extended’ trait assessment after 10 weeks, and estimation of trait prevalence. Results: Recruitment ceased with 29/50 participants after 14 months due to difficulties associated with COVID‐19. Recruitment rate: 29/118 (25%) of those invited to participate (95% CI 17 to 33). 24/26 (92%) participants found the intervention acceptable and were willing to participate in a future study. After 10 weeks, 65% remained not well controlled (ACQ‐5 > 1) and would have required the ‘extended’ assessment. Participants had a mean (SD) 4.8 (2.3) of 13 traits assessed. ACQ‐5 improved during the study by −1.0 (0.3 to 1.8) units, and post‐bronchodilator airflow limitation reduced from 59% of participants to 35%. 12/29 (41%) participants received continuous oral corticosteroids at some point during the study. Conclusion: Protocolised treatable trait management was acceptable to participants, associated with significant clinical benefit, and a full RCT appears feasible. Targeting type‐2 inflammation and airflow obstruction was insufficient to control asthma in the majority of patients, despite marked systemic corticosteroid exposure. Trial Registration: ACTRN12620000935932
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of Record, Version of record, pdf, 977.9KB, Terms of use)
-
- Publisher copy:
- 10.1111/resp.70016
Authors
Contributors
+ Fingleton, J
- Role:
- Contributor
+ McDonald, VM
- Role:
- Contributor
+ Hardy, J
- Role:
- Contributor
+ McLachlan, R
- Role:
- Contributor
+ Gibson, PG
- Role:
- Contributor
+ Health Research Council of New Zealand
More from this funder
- Funder identifier:
- https://ror.org/00zbf3d93
- Publisher:
- Wiley
- Journal:
- Respirology More from this journal
- Publication date:
- 2025-03-12
- Acceptance date:
- 2025-02-05
- DOI:
- EISSN:
-
1440-1843
- ISSN:
-
1323-7799
- Language:
-
English
- Keywords:
- Pubs id:
-
1596117
- Local pid:
-
pubs:1596117
- Source identifiers:
-
2767803
- Deposit date:
-
2025-03-13
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
If you are the owner of this record, you can report an update to it here: Report update to this record